TOXICITY AND OUTCOMES OF RITUXIMAB WITH LMB-96 IN PEDIATRIC HIGH-RISK B-CELL NON- HODGKIN LYMPHOMA: A COMPARATIVE STUDY FROM A LOW- AND MIDDLE-INCOME COUNTRY (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 167; Pres time: Sep 17, 2026; Location: Exhibition Area; "Adding rituximab to LMB-96 is feasible and safe in an LMIC cohort, showing no increase in acute toxicity or infusion reactions. Comparable survival between groups likely reflects the higher baseline risk in the rituximab-treated cohort. Elevated LDH remains a critical prognostic factor, emphasizing the need for better risk-adapted strategies in resource-limited settings."
Clinical • B Cell Non-Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma • Pediatrics
|
|
Walaa Elsayed1; Fatma Soufi2; Sara Metwally3; Shaimaa Abdalgeleel4; Hany Abdelrahman3
|